NCT00678730|CompletedEarly Phase 1FDA Drug
Loading search results
Sponsor study identifier
interventional
72
1 country
1
Study Start
August 23, 2007
Actual (reported)Primary Completion
September 11, 2014
Actual (reported)Study Completion
September 11, 2014
Actual (reported)This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 11, 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 23, 2007
Actual (reported)May 13, 2008
Actual (reported)May 15, 2008
Actual (reported)September 11, 2014
Actual (reported)September 11, 2014
Actual (reported)Behavioral Measures
Baseline, +15, +25, +60, +300
* Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or "joint". * Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or "joint". * Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or "joint".
small amount of ethanol, (quarter teaspoon), with no THC
0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
VA Connecticut Healthcare System
West Haven, Connecticut, 06516, United States
Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D'Souza DC. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2019 Nov;236(11):3209-3219. doi: 10.1007/s00213-019-05273-5. Epub 2019 Jun 11.
Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Andrew Sewell R, Skosnik PD, D'Souza DC. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):176-183. doi: 10.1016/j.pnpbp.2017.06.019. Epub 2017 Jun 20.
Deepak D'Souza, M.D.
Yale University
72 participants (actual enrollment reported by the registry).
First Submitted
May 13, 2008
First Posted
May 15, 2008
Study Start
August 23, 2007
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
September 11, 2014
Actual (reported)Study Completion
September 11, 2014
Actual (reported)Last Updated
March 9, 2022
Record last verified: 2022-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: